Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing

By Reuters News

- Recursion Pharmaceuticals, Inc. RXRX.O:

  • RECURSION PHARMACEUTICALS - ENTERS AMENDMENT TO MASTER AGREEMENT WITH TEMPUS ON SEPT 15, 2026 - SEC FILING

  • RECURSION PHARMACEUTICALS - EXTENDS AGREEMENT TERM FROM FIVE TO SIX YEARS - SEC FILING

  • RECURSION PHARMACEUTICALS - ELIMINATES CO'S RIGHT TO TERMINATE AGREEMENT FOR CONVENIENCE - SEC FILING

Source text: [ID:n0001601830-26-000112]

Further company coverage: RXRX.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk